anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of drug controlled-release carrier materials, and particularly relates to a PVA-GG-based double-layer heterogeneous microgel delivery system and application thereof in preparation of colitis treatment. The PVA-GG based bilayer heterogeneous microgel delivery system comprises the following components: the inner layer is made of polyvinyl alcohol (PVA) and Guar Gum (GG), the outer layer is modified with a layer of SA hydrogel, CS is used for carrying out polyelectrolyte membrane modification on the outermost layer and SA, and curcumin Cur is used as an experimental drug for carrying out drug loading. The dual layer microgel has different matrix materials inside and outside, and thus can serve as a delivery system with multiple functions in one body. Is helpful for improving the solubility and the absorption performance of the curcumin. The hydrogel can be orally taken to effectively reduce the burst release and premature release behavior of the Cur anti-inflammatory drug in the gastrointestinal tract. The results of in vivo pharmacodynamic experiments show that CUR @ gels can be effectively gathered at the colon part, relieve the inflammatory condition, reduce the weight of a mouse, improve the colon shortening and reduce the inflammatory level.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to pharmaceutical industry, in particular to composition for treatment of proliferative and/or inflammatory condition. Composition, which contains water extract of chamomile flowers, and water extract consists of essential oil, which is obtained by extraction process, including distillation with water steam of chamomile flowers, and oil of Nigella sativa for treatment of proliferative and/or inflammatory condition. Application of composition for obtaining medication for treatment of proliferative and/or inflammatory condition. Method of treating proliferative and/or inflammatory condition, which includes introducing to patient composition in effective quantity. ^ EFFECT: composition acts synergistically and is effective for treatment of proliferative and/or inflammatory condition. ^ 27 cl, 18 dwg, 3 ex
AIM: Vascular and peritoneal access are essential elements for sustainability of chronic dialysis programs. Data on availability, patterns of use, funding models, and workforce for vascular and peritoneal accesses for dialysis at a global scale is limited.
METHODS: An electronic survey of national leaders of nephrology societies, consumer representative organizations, and policymakers was conducted from July to September 2018. Questions focused on types of accesses used to initiate dialysis, funding for services, and availability of providers for access creation.
RESULTS: Data from 167 countries were available. In 31 countries (25% of surveyed countries), >75% of patients initiated haemodialysis (HD) with a temporary catheter. Seven countries (5% of surveyed countries) had >75% of patients initiating HD with arteriovenous fistulas or grafts. Seven countries (5% of surveyed countries) had >75% of their patients starting HD with tunnelled dialysis catheters. 57% of low-income countries (LICs) had >75% of their patients initiating HD with a temporary catheter compared to 5% of high-income countries (HICs). Shortages of surgeons to create vascular access were reported in 91% of LIC compared to 46% in HIC. Approximately 95% of participating countries in the LIC category reported shortages of surgeons for peritoneal dialysis (PD) access compared to 26% in HIC. Public funding was available for central venous catheters, fistula/graft creation, and PD catheter surgery in 57%, 54% and 54% of countries, respectively.
CONCLUSION: There is a substantial variation in the availability, funding, workforce, and utilization of vascular and peritoneal access for dialysis across countries regions, with major gaps in low-income countries.
Kidney stone disease (KSD) is a major public health concern associated with high morbidity and recurrence, places a significant burden on the health care system worldwide. Calcium oxalate (CaOx) alone or a mixture of CaOx and calcium phosphate stones accounting for more than 80 % of cases. However, beyond surgical removal, the prevention and reduction of recurrence of CaOx kidney stones have always been a challenge. Given that macrophages are traditional innate immune cells that play critical roles in the clearance of pathogens and the maintenance of tissue homeostasis, which have gained more and more interests in nephrolithiasis. Several studies recently clearly demonstrated that M2-macrophage could reduce the renal calcium oxalate (CaOx) crystal acumination, and provide premise insights and therapeutic options for KSD by modulating the macrophage phenotypes. However, the mechanism of macrophage-polarization regulation and that effects on kidney stone prevention and treatments are far from clear. Here, we comprehensively reviewed the literatures related to cytokines, epigenetic modifications and metabolic reprograming of macrophage in CaOx kidney stone disease, aimed to provide better understandings on macrophage polarization regulation as well as its potential clinical applications in CaOx kidney stone disease treatments and prevention.
Hecogenin is prepared from a crude product obtained from agave leaves by hydrolysis of the heconin contained in the leaves by producing from the crude product a solution of hecogenin in a solvent mixture containing at least one organic polar solvent for hecogenin, at least one organic non-polar non-solvent for hecogenin and a controlled amount of water to induce separation of the solution into two phases and recovering hecogenin from the upper phase. When the moisture content of the crude hecogenin is relatively high, the extraction may be carried out with the solvent and non-solvent direct. A suitable polar solvent is methanol and a suitable non-polar solvent is a saturated or unsaturated aliphatic hydrocarbon which is liquid at room temperature. The above process may be modified in any of the following ways: (a) the crude hecogenin is extracted with the solvent for hecogenin, the resulting extract is mixed with the non-solvent for hecogenin and water in such proportions that two phases are formed, and the upper phase is withdrawn for hecogenin recovery; (b) the crude hecogenin is extracted with a mixture of the solvent and the non-solvent for hecogenin, the resulting extract is mixed with so much water than two phases are formed and the upper phase is withdrawn for hecogenin recovery; (c) the crude hecogenin is extracted with a mixture of the solvent for hecogenin and water, and the resulting aqueous extract is mixed with the non-solvent for hecogenin to form two phases, and hecogenin is recovered from the withdrawn upper phase; and (d) the crude hecogenin is extracted with the mixture of the solvent and non-solvent for hecogenin and water at a temperature at which the said mixture forms a homogenous phase, the extract is cooled to cause phase separation, and the hecogenin is recovered from the withdrawn upper phase.  The latter modified method is suitable for a process carried out in a continuous manner. The hecogenin extracted by the above process may be further purified, for example, by boiling a methanolic solution of the purified hecogenin in the presence of charcoal. Specifications 974,876 and 974,878 are referred to.
A 74-week study was conducted in mice using dietary levels of bromocriptine mesylate equivalent to oral doses of 10 and 50 mg/kg/day. A 100-week study in rats was conducted using dietary levels equivalent to oral doses of 1.7, 9.8, and 44 mg/kg/day. The highest doses tested in mice and rats were approximately 2.5 and 4.4 times, respectively, the maximum human dose administered in controlled clinical trials (100 mg/day) based on body surface area. Malignant uterine tumors, endometrial and myometrial, were found in rats as follows: 0/50 control females, 2/50 females given 1.7 mg/kg daily, 7/49 females given 9.8 mg/kg daily, and 9/50 females given 44 mg/kg daily. The occurrence of these neoplasms is probably attributable to the high estrogen/progesterone ratio which occurs in rats as a result of the prolactin-inhibiting action of bromocriptine mesylate. The endocrine mechanisms believed to be involved in the rats are not present in humans. There is no known correlation between uterine malignancies occurring in bromocriptine-treated rats and human risk. In contrast to the findings in rats, the uteri from mice killed after 74 weeks of treatment did not exhibit evidence of drug-related changes.

Bromocriptine mesylate was evaluated for mutagenic potential in the battery of tests that included Ames bacterial mutation assay, mutagenic activity in vitro on V79 Chinese hamster fibroblasts, cytogenetic analysis of Chinese hamster bone marrow cells following in vivo treatment, and an in vivo micronucleus test for mutagenic potential in mice. 

No mutagenic effects were obtained in any of these tests.

Fertility and reproductive performance in female rats were not influenced adversely by treatment with bromocriptine beyond the predicted decrease in the weight of pups due to suppression of lactation. In males treated with 50 mg/kg of this drug, mating and fertility were within the normal range. Increased perinatal loss was produced in the subgroups of dams, sacrificed on day 21 postpartum (p.p.) after mating with males treated with the highest dose (50 mg/kg).
The present invention relates to functional-gel compositions as medicaments, foods, food ingredients, food supplements and to uses and methods. The functional-gels comprise an edible gelling agent and additionally a dietary protein or a dietary fiber or a combination of both. The functional-gel compositions when consumed in a sufficient amount as a supplement to a diet, meal or snack promote satiety and reduce energy intake in a subject in need thereof. The functional-gels are useful for improving weight management and promoting health. The functional-gels are useful for the treatment or prevention of over-weight, obesity and related conditions in a subject in need thereof. The functional-gel compositions may be formulated in a variety of ways to provide acceptable taste and texture, including for example as health bars, confections or as ready-to-eat, ready-to-drink, shelf stable and single-serve packaged foods.
Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
Provided is a novel method for inferring a depressive state using a wearable device. Each data type of biological data for several days from a plurality of subjects is converted into data for each predetermined unit time such as one hour (S201). Next, the quantile of the distribution of obtained sample data is determined for each subject and each data type (S202). The standard deviation of the distribution of the obtained sample data is also calculated for each subject and each data type (S203). The Pearson correlation coefficient is calculated for each combination of data types for each subject (S204). Next, an inference model for the problem of determining whether a subject is classified as being in a depressive state or not is trained by machine leaning using teacher data in which the feature amounts of the quantile, the standard deviation, and the Pearson correlation coefficient extracted from the biological data of each subject are used as input vectors and evaluation of the depressive state for each subject by an expert such as a doctor is used as a label (S206).
310,056. Schering-Kahlbaum Akt.- Ges. April 21, 1928, [Convention date]. Medicines for internal use.-Ovarial hormone and the hormone of the anterior lobe of the pituitary gland are obtained from the urine, of pregnant individuals by stirring the preferably concentrated urine with adsorbents such as carbon or kieselguhr or by filtration therethrough. The hormones are extracted from the separated adsorbent material by fractional treatment with solvents; the ovarial hormone being first extracted with an organic solvent, and the pituitary hormone then obtained by extracting the adsorbent with an aqueous liquid of suitable hydrogen ion concentration. Alternatively the urine may be first freed from a specific hormone and subsequently treated with an adsorbent. According to examples (1) silica gel is stirred with urine, filtered off, and extracted first with chloroform to obtain ovarial hormone and then with water rendered alkaline with caustic soda lye to extract the hypophysis hormone; (2) animal charcoal is stirred with concentrated urine, filtered off, dried, and extracted successively with ether and water; (3) concentrated urine is extracted with ether to remove ovarial hormone, and shaken with kaolin, which is then removed and extracted with water containing a little carbolic acid.
This is an open label study that will be conducted in infants and children presenting for procedures (eg., surgery or cardiac catheterization) at Stanford and Lucile Packard Children's hospital in California and at The Children's Hospital in Denver, CO. Patients with abnormal kidney or liver functions will be excluded from the study as the dysfunction in these organs affects the clearance of medications from the body and affects dosing. Preterm neonates will also be excluded. All patients will be premedicated and anesthetised at the discretion of the anesthesia faculty providing clinical care for the child. Once the patient's procedure is underway, a 0.5 cc blood sample will be drawn from an intravenous line. This is the preload blood sample (T0). Following this a 2mg/kg intravenous bolus of Ketamine will be administered over 5 minutes (this is the usual dose and manner in which ketamine is administered). Five minutes after the bolus, timed blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus. (Total 14 blood samples; total blood required is 7 mls for the entire study). When the procedure is completed the anesthesiologist will awaken the patient as per their usual practice. Blood samples that still need drawing will be done in the post-anesthesia recovery room or intensive care or ward-any location where the patient is likely to remain after the surgery.
The trial is a randomised, open, dose-selection, single centre trial. One adjuvant will be assessed, aluminum hydroxide (alum). Three different dosages - 10µg, 30µg, and 100µg - of GMZ2 will be evaluated with the aluminum hydroxide adjuvant. A total of 30 volunteers will be enrolled and randomized into three groups of 10. As this is a dose escalation study, volunteers in Group 1 will receive the initial dose of 10µg on the first vaccination day. After a satisfactory safety profile at this dose (see sections 6.2.2 and 6.2.3), we will proceed to vaccinate volunteers in Group 2 with the higher dose of 30µg after a 2-week interval. The same procedure will also be followed for volunteers in Group 3, who will be administered their initial dose of 100µg GMZ2 if the review of the safety profile of Group 2 is satisfactory. The aim will be to recruit all volunteers before the intended start of the study. The randomization procedure will be performed in the following way: when participants are found to be eligible and have signed their informed consent they will be numbered sequentially (in order of enrollment). The numbers will be randomly assigned to 3 groups of 10 numbers through a specific randomization computer program. These groups will be the treatment groups.
This review aimed to examine the effects of curcumin on chronic inflammatory metabolic disease by extensively evaluating meta-analyses of randomized controlled trials (RCTs). We performed a literature search of meta-analyses of RCTs published in English in PubMed®/MEDLINE up to 31 July 2023. We identified 54 meta-analyses of curcumin RCTs for inflammation, antioxidant, glucose control, lipids, anthropometric parameters, blood pressure, endothelial function, depression, and cognitive function. A reduction in C-reactive protein (CRP) levels was observed in seven of ten meta-analyses of RCTs. In five of eight meta-analyses, curcumin intake significantly lowered interleukin 6 (IL-6) levels. In six of nine meta-analyses, curcumin intake significantly lowered tumor necrosis factor α (TNF-α) levels. In five of six meta-analyses, curcumin intake significantly lowered malondialdehyde (MDA) levels. In 14 of 15 meta-analyses, curcumin intake significantly reduced fasting blood glucose (FBG) levels. In 12 of 12 meta-analyses, curcumin intake significantly reduced homeostasis model assessment of insulin resistance (HOMA-IR). In seven of eight meta-analyses, curcumin intake significantly reduced glycated hemoglobin (HbA1c) levels. In eight of ten meta-analyses, curcumin intake significantly reduced insulin levels. In 14 of 19 meta-analyses, curcumin intake significantly reduced total cholesterol (TC) levels. Curcumin intake plays a protective effect on chronic inflammatory metabolic disease, possibly via improved levels of glucose homeostasis, MDA, TC, and inflammation (CRP, IL-6, TNF-α, and adiponectin). The safety and efficacy of curcumin as a natural product support the potential for the prevention and treatment of chronic inflammatory metabolic diseases.
Opioid abuse is a significant global public health problem. Of the more than one million people suffering today from opiate dependency, less than a quarter of such individuals receive treatment. Pharmacotherapeutic approaches traditionally have targeted mu opioid receptors since heroin and its metabolites bind with highest affinity to this receptor subtype. Although such treatment strategies have improved substance abuse outcomes, they do not effectively block opiate craving and thus are still associated with high rates of relapse. Using a strategy of indirectly regulating neural systems to modulate opioid-related behavior, our preclinical rodent studies consistently demonstrated that cannabidiol (CBD), a nonpsychoactive component of cannabis, specifically inhibited cue-induced heroin-seeking behavior. CBD's selective effect on drug-seeking behavior was pronounced after 24 hrs and endured even two weeks after the last drug administration following short-term CBD exposure. The fact that drug craving is generally triggered by exposure to conditioned cues suggests that CBD might be an effective treatment for heroin craving, specially given its protracted impact on behavior. CBD has already been shown in Phase I of our study and in various clinical studies to be well tolerated with a wide safety margin in human subjects. CBD thus represents a strong candidate for the development as a potential therapeutic agent in humans for opioid craving and relapse prevention. It is the goal of this second exploratory phase of the project to characterize the effects of CBD administration on cue-induced craving in drug-abstinent heroin-dependent subjects using a random double blind design during a post-acute (greater than 6 days since last use) heroin withdrawal period. Study participants will be administered CBD during 3 test sessions and studied for the effects on cue-induced craving during those sessions as well as one week after the final CBD administration on the final test day (session 4).
Systems and methods for use in classifying and measuring images of skin abnormalities. The systems and methods can be used in an AR enabled system that may be used to assist in skin surgeries and skin abnormality triaging and diagnosis. The system uses a convolutional neural network to classify a skin abnormality in an initial image. The CNN may also be used in determining the boundaries of the skin abnormality. A fiducial marker may be present in the initial image and this marker may be used in automatically measuring the size of the skin abnormality. An adjusted image is generated based on the measured abnormality and this adjusted image can be used as an overlay in an AR enabled system for use in assisting surgical procedures.
Flossing is universally recognized in the dental profession as a primary component of oral hygiene. Data supports the correlation between flossing and disease prevention by ways of reducing gingival bleeding, gingivitis, and dental caries.(1, 2) However, a recent AP publication (3) questioning the validity of flossing as an efficacious preventative method has warranted that oral healthcare professionals address certain underlying assumptions about the practice. Specifically, there is a clear gap in the number of clinical effectiveness trials that measure the ability of flossing for the sole purpose of oral plaque biofilm removal. Such studies are urgently needed. At this moment we can only assume flossing's correlation with disease prevention also links flossing with effectively removing oral plaque biofilm. Due to the current research gaps, additional studies must be performed to address the needs highlighted by the absence of substantive research in this field.

Our long term goal is to evaluate if flossing is an effective oral health aid in the removal of oral plaque biofilm. The overall objective of this application is to provide a consistent measurement to confirm whether flossing is an effective oral care technique in removing disease causing oral plaque biofilm . The rationale that underlies this proposal comes from the many professional associations, such as the American Dental Association, American Dental Hygienists' Association, and the U.S. Department of Health and Human Services, that endorse flossing as an effective home care routine in oral disease prevention. Many oral health professionals would argue that flossing is effective in plaque removal, as they have seen the results anecdotally year after year, yet it is clear that additional studies are needed to move what is known anecdotally to what is known scientifically.
The sialic acid component of a sialic acid unit-containing cell surface marker characteristic of cancerous mammalian cells, such as .alpha.2-8 polysialic acid, is modified, so that cells normally expressing such a marker express instead a modified sialic acid unit-containing cell surface marker which is strongly immunogenic. For example, the present invention enables, in a portion of patient cells which regularly express .alpha.2-8 polysialic acid (i.e. various types of cancer cells), the expression of a highly immunogenic surface antigen namely, modified .alpha.2-8 polysialic acid. The modification is suitably N-acylation of a precursor of the sialic acid, so that the N-acylated precursor becomes chemically incorporated in the polysialic acid during its intracellular biochemical synthesis.  Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as .alpha.2-8 polysialic acid) and a protein, can then be used to eliminate cells which express .alpha.2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker, or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.